Susan C. Adeniyi-Jones, MD
NeonatologyInsurance Accepted
- Aetna Better Health PA Kids HMO
- Aetna HMO
- Aetna PPO/POS/EPO
- Cigna/Great West HMO EPO POS
- Cigna/Great West PPO
- Fidelis Care NJ Medicaid HMO
- First Health/Affordable PPO
- Geisinger Health Plan Commercial
- Highmark Blue Cross Blue Shield of Delaware *PA Loc Contiguous to DE*
- Highmark Blue Cross Blue Shield of Delaware *PA Loc NONContiguous to DE*
- Highmark Blue Cross Blue Shield of Pennsylvania
- Highmark Medicaid Health Options
- Highmark Medicaid Health Options - Delaware & Chester CTY & TJU Sites ONLY
- Horizon Blue Cross Blue Shield of New Jersey
- Independence Blue Cross/Amerihealth/Keystone Health Plan
- Insurance Administrators of America
- INTEGRA Administrative Group (ClaimsBridge)
- Keystone First CHIP
- Keystone First Medicaid HMO
- New Jersey Medicaid
- Olympus Managed Healthcare PPO DE/PA
- Pennsylvania Medicaid
- Preferred Healthcare PPO
- Private Health Care Systems (PHCS)
- Six Degrees Health Transplant
- Six Degrees Health-Lucent
- Star Healthcare Network
- Three Rivers Provider Network
- Tricare/Humana Military Health Services/CHAMPVA
- United Healthcare HMO/POS/PPO/EPO
- UPMC Medicaid/CHIP
- US Family Health Plan
-
Buprenorphine vs. morphine: impact on neonatal opioid withdrawal syndrome (NOWS) outcomes in a single center retrospective study; Journal of Perinatology; (2025).
-
Abstinence scoring algorithms for treatment of neonatal opioid withdrawal syndrome (NOWS); Journal of Perinatology; (2024).
-
Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial; Journal of Perinatology; (2023).
-
Algorithms for treatment of Neonatal Opioid Withdrawal Syndrome (NOWS) based on Modified and Abbreviated Finnegan Symptom Score; Unknown Source; (2023).
-
Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome.; Pediatric research; (2022).
-
Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome; Clinical and Translational Science; (2021).
-
The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome; Clinical Pharmacology & Therapeutics; (2018).
-
Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome.; The New England journal of medicine; (2017).
- English